PhRMA Feels Deadline Pressure, Reminds FDA Of Flexibility In PDUFA Goals

The Pharmaceutical Research & Manufacturers of America is suggesting that FDA can miss its user fee deadline for a product if prolonging the review would lead to swifter approval than entering a second cycle